Tyler GolatoinMolecule BlogIntroducing IP Tokens (IPTs): A New Incentive for Scientific Collaboration“Show me the incentive and I’ll show you the outcome” — Charlie MungerJul 11, 2023Jul 11, 2023
Tyler GolatoinMolecule BlogThe Emergence of Biotech DAOsA blossoming Decentralized Science (DeSci) movement is changing the biopharma landscape by enabling the formation of patient- and…Jan 28, 20222Jan 28, 20222
Tyler GolatoinMolecule BlogIP-NFTs for Researchers: A New Biomedical Funding ParadigmTL;DR: This week, the first university biomedical intellectual property (IP) and research project was funded as an NFT (non-fungible…Aug 19, 2021Aug 19, 2021
Tyler GolatoinMolecule BlogMolecule and the Search for Longevity TherapeuticsIn a few short weeks, we will be launching one of our flagship longevity projects with the University of Copenhagen’s Center for Healthy…Oct 1, 2020Oct 1, 2020
Tyler GolatoinMolecule BlogThe Impact of COVID-19 on Science, Publishing, and Drug DevelopmentThe Defining Event of Our LifetimesApr 24, 2020Apr 24, 2020
Tyler GolatoinMolecule BlogMolecule and Arctoris announce partnership to tackle the innovation crisis in drug development.The pharmaceutical industry is facing a wide variety of challenges, but perhaps the most pressing is the ongoing innovation crisis. Drug…Feb 10, 2020Feb 10, 2020
Tyler GolatoinMolecule BlogFunding Late Stage Clinical Development of a Novel AntimalarialMolecule Case Study SeriesJun 4, 2019Jun 4, 2019
Tyler GolatoinMolecule BlogThe Future of Drug Development is OpenPharma Macroeconomics: A Looming CrisisApr 9, 2019Apr 9, 2019
